The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zakharov D.V.

Central City Clinical Hospital;
Jaroslav the Wise Novgorod State University

Buriak Iu.V.

Bekhterev National Medical Research Centerfor Psychiatry and Neurology

Mikhailov V.A.

Tardive neuroleptic-induced dyskinesias

Authors:

Zakharov D.V., Buriak Iu.V., Mikhailov V.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1): 31‑35

DOI: 10.17116/jnevro202212201131

Read: 13243 times

Download PDF (RU)
Contact the author
Table of contents

TARDIVE NEUROLEPTIC-INDUCED DYSKINESIAS
TARDIVE NEUROLEPTIC-INDUCED DYSKINESIAS

To cite this article:

Zakharov DV, Buriak IuV, Mikhailov VA. Tardive neuroleptic-induced dyskinesias. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1):31‑35. (In Russ.)
https://doi.org/10.17116/jnevro202212201131

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Drugs that block dopaminergic transmission are currently widely used in the treatment of psychiatric diseases. One of the significant, common complications of therapy are tardive dyskinesias, which develop after prolonged, at least 3 months, therapy with antipsychotics and significantly reduce the quality of life of patients. Tardive dyskinesia is an extrapyramidal disorder, mainly manifested by involuntary hyperkinesis of the muscles of the face and tongue. These movements negatively affect the patient’s daily activities and quality of life. This article reviews the currently available treatment strategies for this type of disorder. One of the promising methods is therapy with Normokinesin (tetrabenazine), which, by reducing dopaminergic stimulation of brain neurons, significantly reduces hyperkinesis.

Keywords:

tardive dyskinesia
tardive dyskinesia
neuroleptics
tetrabenazine
Normokineztine

Authors:

Zakharov D.V.

Central City Clinical Hospital;
Jaroslav the Wise Novgorod State University

Buriak Iu.V.

Bekhterev National Medical Research Centerfor Psychiatry and Neurology

Mikhailov V.A.

Received:

29.11.2021

Accepted:

18.12.2021

Close metadata

References:

  1. Caroff SN, Campbell EC. Drug-Induced Extrapyramidal Syndromes. Psychiatric Clinics of North America. 2016;39(3):391-411.  https://doi.org/10.1016/j.psc.2016.04.003
  2. Zalyalova ZA. Modern classifications of muscular dystonia, treatment strategy. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(3):85-89. (In Russ.).
  3. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor and Other Hyperkinetic Movements (New York, NY). 2013;3:34-38.  https://doi.org/10.7916/D88P5Z71
  4. Boyd KN, Mailman RB. Dopamine Receptor Signaling and Current and Future Antipsychotic Drugs. Handb Exp Pharmacol. 2012;(212):53-86.  https://doi.org/10.1007/978-3-642-25761-2_3
  5. Mehta SH, Morgan JC, Sethi KD. Drug-induced Movement Disorders. Neurologic Clinics. 2015;33(1):153-174.  https://doi.org/10.1016/j.ncl.2014.09.011
  6. Sethi KD. Movement Disorders Induced by Dopamine Blocking Agents. Seminars in Neurology. 2001;21(01):059-068.  https://doi.org/10.1055/s-2001-13120
  7. Witter DP, Holbert RC, Suryadevara U. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients. Expert Opinion on Pharmacotherapy. 2017;18(10):965-972.  https://doi.org/10.1080/14656566.2017.1323874
  8. Aosaki T, Miura M, Suzuki T, et al. Acetylcholine-dopamine balance hypothesis in the striatum: An update. Geriatrics & Gerontology International. 2010;10:148-157.  https://doi.org/10.1111/j.1447-0594.2010.00588.x
  9. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use. The Journal of Clinical Psychiatry. 2017;78(3):264-278.  https://doi.org/10.4088/JCP.16r10832
  10. Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opinion on Pharmacotherapy. 2016;17(18):2461-2470. https://doi.org/10.1080/14656566.2016.1258063
  11. Caroff SN, Yeomans K, Lenderking WR, et al. RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings. Journal of Clinical Psychopharmacology. 2020;40(3):259-268.  https://doi.org/10.1097/JCP.0000000000001201
  12. Ma HI, Saint-Hilaire M, Thomas CA, et al. Stigma as a key determinant of health-related quality of life in Parkinson’s disease. Quality of Life Research. 2016;25(12):3037-3045. https://doi.org/10.1007/s11136-016-1329-z
  13. Caroff SN, Davis VG, Miller DD, et al. Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia. The Journal of Clinical Psychiatry. 2011;72(03):295-303.  https://doi.org/10.4088/JCP.09m05793yel
  14. Margolius A, Fernandez HH. Current treatment of tardive dyskinesia. Parkinsonism & Related Disorders. 2019;59:155-160.  https://doi.org/10.1016/j.parkreldis.2018.12.022
  15. Yassa R, Nair NP. A 10-year follow-up study of tardive dyskinesia. Acta Psychiatrica Scandinavica. 1992;86(4):262-266.  https://doi.org/10.1111/j.1600-0447.1992.tb03264.x
  16. Gardos G, Casey D, Cole J, Perenyi A. Ten-year outcome of tardive dyskinesia. American Journal of Psychiatry. 1994;151(6):836-841.  https://doi.org/10.1176/ajp.151.6.836
  17. Quitkin F, Rifkin A, Gochfeld L. Tardive dyskinesia: are first signs reversible? American Journal of Psychiatry. 1977;134(1):84-87.  https://doi.org/10.1176/ajp.134.1.84
  18. Jeste D, Potkin S, Sinha S, et al. Tardive Dyskinesia—Reversible and Persistent. Archives of General Psychiatry. 1979;36(5):585-590.  https://doi.org/10.1001/archpsyc.1979.01780050095012
  19. Zutshi D, Cloud LJ, Factor SA. Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic. Tremor and Other Hyperkinetic Movements (New York, NY). 2014;4:266-270.  https://doi.org/10.7916/D8MS3R8C
  20. Caroff SN, Mu F, Ayyagari R, et al. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. BMC Psychiatry. 2018;18(1):306-310.  https://doi.org/10.1186/s12888-018-1889-2
  21. Egan MF, Apud J, Wyatt RJ. Treatment of Tardive Dyskinesia. Schizophrenia Bulletin. 1997;23(4):583-609.  https://doi.org/10.1093/schbul/23.4.583
  22. Mentzel CL, Bakker PR, van Os J, et al. Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness. The Journal of Clinical Psychiatry. 2017;78(3):279-285.  https://doi.org/10.4088/JCP.16m11049
  23. Soares-Weiser K, Fernandez H. Tardive Dyskinesia. Seminars in Neurology. 2007;27(2):159-169.  https://doi.org/10.1055/s-2007-971169
  24. Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. The American Journal of Psychiatry. 1973;130(4):479-483. 
  25. Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463-469.  https://doi.org/10.1212/WNL.0b013e31829d86b6
  26. Mentzel TQ, van der Snoek R, Lieverse R, et al. Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia. The Journal of Clinical Psychiatry. 2018;79(6):45-59.  https://doi.org/10.4088/JCP.17r11852
  27. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of Newer Antipsychotics on Extrapyramidal Function. CNS Drugs. 2002;16(1):23-45.  https://doi.org/10.2165/00023210-200216010-00003
  28. Hyde T, Apud J, Fisher W, Egan M. Drug Induced Movement Disorders. 2nd ed. (Factor S, Lang A, Weiner W, eds.). Malden: Blackwell Publishing; 2005.
  29. Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. Journal of the Neurological Sciences. 2018;389:67-75.  https://doi.org/10.1016/j.jns.2018.02.010
  30. El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H. Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews. 2018;12(1):12-19.  https://doi.org/10.1002/14651858.CD000458.pub3
  31. Chan CH, Chan HY, Chen YC. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia. International Clinical Psychopharmacology. 2018;33(3):155-162.  https://doi.org/10.1097/YIC.0000000000000208
  32. Caroff SN, Campbell EC, Carroll B. Pharmacological treatment of tardive dyskinesia: recent developments. Expert Review of Neurotherapeutics. 2017;17(9):871-881.  https://doi.org/10.1080/14737175.2017.1358616
  33. Greil W, Haag H, Rossnagl G, Rüther E. Effect of Anticholinergics on Tardive Dyskinesia. British Journal of Psychiatry. 1984;145(3):304-310.  https://doi.org/10.1192/bjp.145.3.304
  34. Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management. Neurology and Therapy. 2018;7(2):233-248.  https://doi.org/10.1007/s40120-018-0105-0
  35. Pappa S, Tsouli S, Apostolou G, et al. Effects of Amantadine on Tardive Dyskinesia. Clinical Neuropharmacology. 2010;33(6):271-275.  https://doi.org/10.1097/WNF.0b013e3181ffde32
  36. Elkurd MT, Bahroo LB, Pahwa R. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson’s disease patients. Neurodegenerative Disease Management. 2018;8(2):73-80.  https://doi.org/10.2217/nmt-2018-0001
  37. Fedorova NV, Vetokhina VN. Diagnosis And Treatment Of Neuroleptic Extrapyramidal Syndromes. Mental Disorders in General Medicine. 2009;3:18-24. (In Russ.).
  38. Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biological Psychiatry. 1993;34(10):713-738.  https://doi.org/10.1016/0006-3223(93)90044-E
  39. Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H. Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews. 2018;2018(3):CD000207 . https://doi.org/10.1002/14651858.CD000207.pub2
  40. Bergman H, Bhoopathi PS, Soares-Weiser K. Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews. 2018;2018(1). https://doi.org/10.1002/14651858.CD000205.pub3
  41. Alabed S, Latifeh Y, Mohammad HA, Bergman H. Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews. 2018;2018(4). https://doi.org/10.1002/14651858.CD000203.pub4
  42. Zakharov DV, Mikhailov VA, Hublarova LA, Zalyalova ZA. Treatment of tardive neuroleptic dyskinesia. Review of Psychiatry and Medical Psychology n.a. V.M. Bekhterev. 2014;3:129-131. (In Russ.).
  43. Pletscher A. Release of 5-Hydroxytryptamine by Benzoquinolizine Derivatives with Sedative Action. Science. 1957;126(3272):507-507.  https://doi.org/10.1126/science.126.3272.507
  44. Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V. Tetrabenazine: Spotlight on Drug Review. Annals of Neurosciences. 2016;23(3):176-185.  https://doi.org/10.1159/000449184
  45. Eiden EL. The vesicular neurotransmitter transporters: current perspectives and future prospects. The FASEB Journal. 2000;14(15):2396-2400. https://doi.org/10.1096/fj.00-0817rev
  46. Eiden LE, Weihe E. VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Annals of the New York Academy of Sciences. 2011;1216(1):86-98.  https://doi.org/10.1111/j.1749-6632.2010.05906.x
  47. Caroff SN, Aggarwal S, Yonan C. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. Journal of Comparative Effectiveness Research. 2018;7(2):135-148.  https://doi.org/10.2217/cer-2017-0065
  48. Citrome L. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Review of Neurotherapeutics. 2018;18(4):323-332.  https://doi.org/10.1080/14737175.2018.1455504
  49. Solmi M, Pigato G, Kane JM, Correll C. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Design, Development and Therapy. 2018;Volume 12:1215-1238. https://doi.org/10.2147/DDDT.S133205
  50. Leung JG, Breden EL. Tetrabenazine for the Treatment of Tardive Dyskinesia. Annals of Pharmacotherapy. 2011;45(4):525-531.  https://doi.org/10.1345/aph.1P312
  51. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48(2):358-362.  https://doi.org/10.1212/WNL.48.2.358
  52. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic disorders. Movement Disorders. 2007;22(2):193-197.  https://doi.org/10.1002/mds.21222
  53. Miguel R, Mendonça MD, Barbosa R, et al. Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study. Therapeutic Advances in Neurological Disorders. 2017;10(2):81-90.  https://doi.org/10.1177/1756285616677004
  54. Factor S, Hauser R, Mandri D, et al. A Phase 2 Study of Valbenazine (NBI-98854) for Treatment of Tardive Dyskinesia: KINECT 2 (S27.007). Neurology. 2016;86(16 suppl):27.007. 
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.